Rezivertinib

(Synonyms: BPI-7711)
1 Cited Publications
Kundenbewertung

Based on 1 publication(s) in Google Scholar

Rezivertinib (BPI-7711) is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI). Rezivertinib exhibits high potency against the common activation EGFR and the resistance T790M mutations. Rezivertinib has excellent central nervous system (CNS) penetration and has antitumor activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

  • Reinheit: 99.62%
  • CAS. Nr.: 1835667-12-3
  • Formel: C27H30N6O3
  • Molecular Weight:486.57
  • Speicherung:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Biologische Aktivität
  • Chemical Information
  • Lösungsmittel & Löslichkeit
  • Reinheit & Dokumentation
  • Verweise
  • Help & FAQs
You May Still Need

Publications Citing Use of MedChemExpress (MCE) Rezivertinib

More

Alle EGFR Isoform-spezifische Produkte anzeigen

More
MOQ
Minimum order quantity
100 mg

Angebot einholen Auf Lager

Other size
Angebot einholen
Please select quantity
Amount: USD 0.00